Clinical Trial Protocol Registry
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients
- Protocol number:
- Hoffmann-La Roche
- Company division:
- Official Scientific Title:
- A randomized, open-label, pilot study of a Fuzeon-containing combination therapy compared with standard combination antiretroviral therapy on viral load in treatment-naïve patients with HIV infection
- Brief summary:
- This study will evaluate the effect of Fuzeon-containing combination therapy compared with standard combination antiretroviral therapy on viral load, efficacy and safety in patients with HIV infection who are treatment naive The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 31.
- Study phase:
- Study type:
- Interventional; Treatment; Non-randomized; Open Label; Uncontrolled; Parallel; Safety/efficacy study
- HIV Infections
- Primary outcome:
- Slope of HIV viral load in HIV-positive patients\n
- Key secondary outcomes:
- Efficacy: HIV-RNA, CD4+, time to failure, proportion of patients with a viral load of <400 and <50 copies/mL.\nSafety: Adverse events; safety laboratory tests\n
- Inclusion criteria:
- adult patients >=18 years of age;
- treatment naive;
- HIV-RNA>10,000 copies/mL;
- late disease or symptomatic HIV infection, with a CD4 count <200 cells/mL, or who have been diagnosed with an AIDS-defining event at any CD4 count.
- Exclusion criteria:
- signs of severe illness;
- abnormal liver enzymes (ALT and AST levels >5 times upper limit of normal);
- women who are pregnant or breastfeeding.
- Males or Females
- Age limits:
- Min: 18 years Max: N/A (No limit)
- Accepts healthy volunteers:
- Anticipated start date:
- June, 2005
- Trial registration date:
- Date last updated:
For more information on a specific Roche trials in your country location, please contact your local Roche affiliate nearest you.
- Go on the URL link- http://www.roche.com and click on the Roche Worldwide tab on the top of the page to locate the country nearest you for contact information.
Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the global studies, please have your healthcare provider contact us and they will be provided with the relevant clinical trial information.
For US or global trials with US sites only, please contact the Trial Information Support Line (TISL)
- 1-888-662-6728 Monday to Friday (6am to 3pm PST)